You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
李氏大藥廠(00950.HK):ES-SCLC的Socazolimab多中心、隨機、雙盲、安慰劑對照第III期臨牀試驗成功招募首名中國患者
格隆匯 07-22 21:55

格隆匯7月22日丨李氏大藥廠(00950.HK)發佈公吿,於2021年7月15日,公司附屬公司中國腫瘤醫療有限公司(COF)已為結合化療一線治療廣泛期小細胞肺癌(ES-SCLC)的Socazolimab(抗PD-L1單克隆抗體,前稱ZKAB001)的多中心、隨機、雙盲、安慰劑對照第III期臨牀試驗,成功招募首名中國患者。臨牀試驗已於2021年3月1日獲得中國國家藥品監督管理局批准。

展開此第III期試驗的依據為先前第Ib期試驗的結果,當中結合卡鉑和依託泊苷的Socazolimab在ES-SCLC患者中表現出良好的療效及安全性。此臨牀試驗涉及56箇中心,由上海市胸科醫院陸舜教授牽頭。

Socazolimab為獲Sorrento Therapeutics,Inc授權於中國、香港、澳門及台灣生產的引進藥品。Socazolimab單藥療法的三個第I期臨牀試驗迄今已完成。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account